InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
jerrybrockman Free
03/23/24 12:43 AM
profile icon
FACT-MASTER Free
02/13/24 3:34 PM
profile icon
FACT-MASTER Free
02/13/24 3:32 PM
profile icon
FACT-MASTER Free
02/02/24 6:54 PM
profile icon
FACT-MASTER Free
01/23/24 4:53 PM
profile icon
FACT-MASTER Free
01/14/24 10:48 AM
profile icon
FACT-MASTER Free
01/11/24 3:57 PM
profile icon
FACT-MASTER Free
01/11/24 3:22 PM
profile icon
FACT-MASTER Free
01/03/24 3:04 PM
profile icon
FACT-MASTER Free
01/03/24 2:25 PM
profile icon
FACT-MASTER Free
01/03/24 9:24 AM
profile icon
Gregg4 Free
12/28/23 3:52 PM
profile icon
investorenquiry Free
12/27/23 7:32 PM
profile icon
FACT-MASTER Free
12/21/23 4:25 PM
profile icon
Newbigtech Free
11/25/23 1:14 PM
profile icon
Monksdream PremiumMember
10/11/23 5:11 PM
profile icon
Paullee Free
10/05/23 10:08 AM
profile icon
Monksdream PremiumMember
09/24/23 12:55 PM
profile icon
Paullee Free
09/22/23 1:54 PM
profile icon
Monksdream PremiumMember
09/21/23 2:25 PM
profile icon
TJG Free
07/06/23 9:43 AM
profile icon
findit PremiumMember
06/15/23 8:31 AM
profile icon
Awl416 Free
03/15/23 5:06 PM
profile icon
Gregg4 Free
03/05/23 8:02 PM
profile icon
goforthebet Free
01/06/22 2:24 PM
profile icon
Jaydixson1 Free
12/15/20 7:26 AM
profile icon
keepemcloser PremiumMember
11/16/20 1:05 PM
profile icon
BuckeyeMike Free
10/01/20 11:17 PM
profile icon
jbeloc Free
09/20/20 10:24 PM
profile icon
keepemcloser PremiumMember
09/03/20 10:15 AM

Esperion Therapeutics Inc (ESPR) RSS Feed

Followers
36
Posters
72
Posts (Today)
0
Posts (Total)
305
Created
12/09/13
Type
Free
Moderators
Esperion is a biopharmaceutical company focused on the research, development and commercialization of potential therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. Many patients with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies. Our lead product candidate, ETC-1002, is a first-in-class orally available small molecule designed to significantly lower elevated levels of LDL-C and improve other cardiometabolic risk factors — without the side effects associated with statin use.
New Post